We recently compiled a list of the 10 Cash-Rich Mid Cap Stocks To Buy Now.In this article, we are going to take a look at where Revolution Medicines, Inc. (NASDAQ:RVMD) stands against the other cash-rich mid cap stocks. Cash flow is the money moving in and out of a business over a set period. It is important because it shows how much cash a company actually has on hand, rather than just looking at profits on paper. There are different types of cash flow, like cash from operating activities, which comes from a company’s main business, and free cash flow, which is the money left after covering expenses and investments. Businesses keep a close eye on their cash flow to make sure they have enough money to pay bills, invest in growth, and avoid financial trouble. Unlike profits, which can be affected by accounting rules, cash flow reflects real money coming in and going out, making it a key measure of financial health. Warren Buffett once said that the key to investing is cash flow. How much money a business brings in and how much it pays out over time is crucial. However, despite this basic principle, many companies do not focus enough on cash flow and how efficiently they use their money. In October 2022, market experts on CNBC’s Halftime Report emphasized the crucial role of free cash flow for businesses. They pointed out that while companies can occasionally rely on external funding from capital markets, they ultimately depend on free cash flow to sustain themselves, since these external financial boosts are not a long-term solution. As the market fluctuates between favoring growth and value stocks, investors tend to gravitate toward familiar territory, which is prioritizing companies with strong free cash flow. Similarly, in late September 2023, Elizabeth Evans, managing partner at Evans May, told CNBC that for the first time in decades, cash holdings are generating returns. She explained that having substantial cash reserves signals strong future purchasing power, which is an encouraging sign for equity investors looking to invest for the long term. In this article, we will take a look at some cash-rich stocks to buy. Our Methodology For this article, we used the Finviz stock screener to identify cash-rich mid-cap stocks. We applied a filter to select companies with market caps between $2 billion and $10 billion. Additionally, we used a current ratio (CR) filter of over 2 to identify stocks with strong current assets. CR is a company’s current assets divided by its current liabilities. If the CR is over 1, it means the company has more assets than liabilities, usually because of high cash reserves, receivables, or inventory. After filtering, we manually searched for companies with cash and cash equivalents exceeding $1 billion as of December 31, 2024 and selected the 10 stocks with the highest cash reserves. The list below is ranked in ascending order based on cash and cash equivalents. We have also included hedge fund sentiment as of Insider Monkey's database of Q4 2024. Story Continues Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A researcher poring over test results, illustrating the breakthrough potential of biotechnology. Revolution Medicines, Inc. (NASDAQ:RVMD) Number of Hedge Fund Holders: 60 Cash and Cash Equivalents as of December 31, 2024: $2,289,299,000 Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage oncology company that focuses on providing targeted therapies for RAS-driven cancers. On December 3, 2024, the company announced that it is raising around $750 million through a stock offering. Revolution planned to sell over 14.1 million shares at $46 each, plus pre-funded warrants for an additional 2.17 million shares. Investors also had the option to buy 2.44 million more shares within 30 days. Prominent banks like JP Morgan and Goldman Sachs led the deal, which was expected to close by December 5, 2024. It is one of the best cash rich stocks to invest in. In December 2024, Revolution Medicines, Inc. (NASDAQ:RVMD) raised $823 million through a public equity offering, strengthening its cash reserves to $2.3 billion. The funds will help expand its product pipeline and prepare for the potential launch of daraxonrasib, after FDA approval is received. R&D spending jumped to $188.1 million in Q4 2024, mainly due to increased clinical trial costs and hiring. Meanwhile, general and administrative expenses dropped to $28.2 million from $32.2 million last year, mostly because of the wind down of EQRx. The company reported a net loss of $194.6 million for the quarter, up from $161.5 million the previous year. In the fourth quarter of 2024, 60 hedge funds were bullish on Revolution Medicines, Inc. (NASDAQ:RVMD), up from 44 funds in the earlier quarter. Farallon Capital was the largest stakeholder of the company, with 13.2 million shares worth $579.5 million. Overall RVMD ranks 4th on our list of the best cash-rich mid cap stocks to buy. While we acknowledge the potential of RVMD as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RVMD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...